{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:40:48Z","timestamp":1792172448319,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI077283"],"award-info":[{"award-number":["R01AI077283"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA213290"],"award-info":[{"award-number":["R01CA213290"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA233770"],"award-info":[{"award-number":["R37CA233770"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) through direct lysis of infected lung epithelial cells, which releases damage-associated molecular patterns and induces a pro-inflammatory cytokine milieu causing systemic inflammation. Anti-viral and anti-inflammatory agents have shown limited therapeutic efficacy. Soluble CD24 (CD24Fc) blunts the broad inflammatory response induced by damage-associated molecular patterns via binding to extracellular high mobility group box 1 and heat shock proteins, as well as regulating the downstream Siglec10-Src homology 2 domain\u2013containing phosphatase 1 pathway. A recent randomized phase III trial evaluating CD24Fc for patients with severe COVID-19 (SAC-COVID; NCT04317040) demonstrated encouraging clinical efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a systems analytical approach, we studied peripheral blood samples obtained from patients enrolled at a single institution in the SAC-COVID trial to discern the impact of CD24Fc treatment on immune homeostasis. We performed high dimensional spectral flow cytometry and measured the levels of a broad array of cytokines and chemokines to discern the impact of CD24Fc treatment on immune homeostasis in patients with COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-two patients were enrolled, and the clinical characteristics from the CD24Fc vs. placebo groups were matched. Using high-content spectral flow cytometry and network-level analysis, we found that patients with severe COVID-19 had systemic hyper-activation of multiple cellular compartments, including CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells, and CD56\n                      <jats:sup>+<\/jats:sup>\n                      natural killer cells. Treatment with CD24Fc blunted this systemic inflammation, inducing a return to homeostasis in NK and T cells without compromising the anti-Spike protein antibody response. CD24Fc significantly attenuated the systemic cytokine response and diminished the cytokine coexpression and network connectivity linked with COVID-19 severity and pathogenesis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data demonstrate that CD24Fc rapidly down-modulates systemic inflammation and restores immune homeostasis in SARS-CoV-2-infected individuals, supporting further development of CD24Fc as a novel therapeutic against severe COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-021-01222-y","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T08:03:58Z","timestamp":1641801838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology"],"prefix":"10.1186","volume":"15","author":[{"given":"No-Joon","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Vilgelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Riesenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsi","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik B.","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrendra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aastha","family":"Khatiwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zequn","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuja","family":"Gunasena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namal P. M.","family":"Liyanage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Bolyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Velegraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Devenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos D.","family":"Malvestutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-927X","authenticated-orcid":false,"given":"Zihai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"1222_CR1","doi-asserted-by":"crossref","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271\u201380.","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"1222_CR2","doi-asserted-by":"crossref","unstructured":"Silva-Lagos LA, Pillay J, van Meurs M, Smink A, van der Voort PHJ, de Vos P. DAMPening COVID-19 severity by attenuating danger signals. Front Immunol. 2021;12:720192.","DOI":"10.3389\/fimmu.2021.720192"},{"issue":"3","key":"1222_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41435-021-00140-w","volume":"22","author":"WG Land","year":"2021","unstructured":"Land WG. Role of DAMPs in respiratory virus-induced acute respiratory distress syndrome-with a preliminary reference to SARS-CoV-2 pneumonia. Genes Immun. 2021;22(3):141\u201360.","journal-title":"Genes Immun"},{"key":"1222_CR4","doi-asserted-by":"publisher","first-page":"7527953","DOI":"10.1155\/2020\/7527953","volume":"2020","author":"S Cicco","year":"2020","unstructured":"Cicco S, Cicco G, Racanelli V, Vacca A. Neutrophil Extracellular Traps (NETs) and damage-associated molecular patterns (DAMPs): two potential targets for COVID-19 treatment. Mediators Inflamm. 2020;2020:7527953.","journal-title":"Mediators Inflamm"},{"issue":"5","key":"1222_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","volume":"20","author":"X Cao","year":"2020","unstructured":"Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269\u201370.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1222_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2107058","volume":"385","author":"MG Thompson","year":"2021","unstructured":"Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320\u20139.","journal-title":"N Engl J Med"},{"issue":"7871","key":"1222_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276\u201380.","journal-title":"Nature"},{"key":"1222_CR8","doi-asserted-by":"crossref","unstructured":"Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med. 2021.","DOI":"10.1056\/NEJMoa2109072"},{"issue":"6","key":"1222_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","volume":"385","author":"L Corey","year":"2021","unstructured":"Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med. 2021;385(6):562\u20136.","journal-title":"N Engl J Med"},{"key":"1222_CR10","doi-asserted-by":"crossref","unstructured":"Consortium WHOST, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for covid-19-interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"issue":"7","key":"1222_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa2031304","volume":"384","author":"VA Simonovich","year":"2021","unstructured":"Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vazquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"1222_CR12","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","volume":"383","author":"JH Stone","year":"2020","unstructured":"Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333\u201344.","journal-title":"N Engl J Med"},{"issue":"8","key":"1222_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693\u2013704.","journal-title":"N Engl J Med"},{"issue":"6","key":"1222_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382\u201393.","journal-title":"Nat Rev Immunol"},{"issue":"5922","key":"1222_CR15","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1126\/science.1168988","volume":"323","author":"GY Chen","year":"2009","unstructured":"Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 2009;323(5922):1722\u20135.","journal-title":"Science"},{"issue":"2","key":"1222_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/cmi.2009.119","volume":"7","author":"X Fang","year":"2010","unstructured":"Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cell Mol Immunol. 2010;7(2):100\u20133.","journal-title":"Cell Mol Immunol"},{"key":"1222_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.antiviral.2018.07.004","volume":"157","author":"RR Tian","year":"2018","unstructured":"Tian RR, Zhang MX, Zhang LT, Zhang P, Ma JP, Liu M, et al. CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS. Antiviral Res. 2018;157:9\u201317.","journal-title":"Antiviral Res"},{"issue":"7","key":"1222_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.it.2007.05.001","volume":"28","author":"Y Liu","year":"2007","unstructured":"Liu Y, Zheng P. CD24: a genetic checkpoint in T cell homeostasis and autoimmune diseases. Trends Immunol. 2007;28(7):315\u201320.","journal-title":"Trends Immunol"},{"issue":"22","key":"1222_CR19","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2013-12-545335","volume":"123","author":"T Toubai","year":"2014","unstructured":"Toubai T, Hou G, Mathewson N, Liu C, Wang Y, Oravecz-Wilson K, et al. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood. 2014;123(22):3512\u201323.","journal-title":"Blood"},{"issue":"10","key":"1222_CR20","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/cyto.a.24213","volume":"97","author":"LM Park","year":"2020","unstructured":"Park LM, Lannigan J, Jaimes MC. OMIP-069: forty-color full spectrum flow cytometry panel for deep immunophenotyping of major cell subsets in human peripheral blood. Cytometry A. 2020;97(10):1044\u201351.","journal-title":"Cytometry A"},{"key":"1222_CR21","doi-asserted-by":"crossref","unstructured":"Zeng C, Evans JP, Pearson R, Qu P, Zheng YM, Robinson RT, et al. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. JCI Insight. 2020;5(22).","DOI":"10.1172\/jci.insight.143213"},{"key":"1222_CR22","doi-asserted-by":"crossref","unstructured":"McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. arXiv preprint arXiv:180203426v3 [statML]. 2020.","DOI":"10.21105\/joss.00861"},{"issue":"4","key":"1222_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cyto.a.20531","volume":"73","author":"K Lo","year":"2008","unstructured":"Lo K, Brinkman RR, Gottardo R. Automated gating of flow cytometry data via robust model-based clustering. Cytometry A. 2008;73(4):321\u201332.","journal-title":"Cytometry A"},{"key":"1222_CR24","doi-asserted-by":"crossref","unstructured":"Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6(2):461\u20134.","DOI":"10.1214\/aos\/1176344136"},{"issue":"7764","key":"1222_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"AC Scott","year":"2019","unstructured":"Scott AC, Dundar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571(7764):270\u20134.","journal-title":"Nature"},{"issue":"4","key":"1222_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.it.2017.02.003","volume":"38","author":"A Kallies","year":"2017","unstructured":"Kallies A, Good-Jacobson KL. Transcription factor T-bet orchestrates lineage development and function in the immune system. Trends Immunol. 2017;38(4):287\u201397.","journal-title":"Trends Immunol"},{"issue":"3","key":"1222_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2307\/2533558","volume":"53","author":"MG Kenward","year":"1997","unstructured":"Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53(3):983\u201397.","journal-title":"Biometrics"},{"key":"1222_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.neucom.2013.09.055","volume":"139","author":"C-Y Liou","year":"2014","unstructured":"Liou C-Y, Cheng W-C, Liou J-W, Liou D-R. Autoencoder for words. Neurocomputing. 2014;139:84\u201396.","journal-title":"Neurocomputing"},{"issue":"5","key":"1222_CR29","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763\u20138.","journal-title":"Anesth Analg"},{"issue":"7","key":"1222_CR30","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/bioinformatics\/btq048","volume":"26","author":"J Gao","year":"2010","unstructured":"Gao J, Tarcea VG, Karnovsky A, Mirel BR, Weymouth TE, Beecher CW, et al. Metscape: a Cytoscape plug-in for visualizing and interpreting metabolomic data in the context of human metabolic networks. Bioinformatics. 2010;26(7):971\u20133.","journal-title":"Bioinformatics"},{"issue":"11","key":"1222_CR31","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498\u2013504.","journal-title":"Genome Res"},{"issue":"1","key":"1222_CR32","first-page":"16","volume":"28","author":"TW Valente","year":"2008","unstructured":"Valente TW, Coronges K, Lakon C, Costenbader E. How correlated are network centrality measures? Connect (Tor). 2008;28(1):16\u201326.","journal-title":"Connect (Tor)"},{"key":"1222_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.biosystems.2014.11.005","volume":"127","author":"Y Tang","year":"2015","unstructured":"Tang Y, Li M, Wang J, Pan Y, Wu FX. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems. 2015;127:67\u201372.","journal-title":"Biosystems"},{"key":"1222_CR34","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. arXiv preprint. arXiv:14065823. 2014."},{"issue":"9","key":"1222_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41577-020-0402-6","volume":"20","author":"Z Chen","year":"2020","unstructured":"Chen Z, John WE. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020;20(9):529\u201336.","journal-title":"Nat Rev Immunol"},{"key":"1222_CR36","doi-asserted-by":"crossref","unstructured":"Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, Monin L, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;26(10):1623-35.","DOI":"10.1038\/s41591-020-1038-6"},{"key":"1222_CR37","doi-asserted-by":"crossref","unstructured":"Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020;5(48).","DOI":"10.1126\/sciimmunol.abd2071"},{"key":"1222_CR38","doi-asserted-by":"crossref","unstructured":"Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508).","DOI":"10.1126\/science.abc8511"},{"key":"1222_CR39","unstructured":"Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, Liew F, Russell CD, Moore SC, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol. 2021;6(57)."},{"issue":"7821","key":"1222_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","volume":"584","author":"C Lucas","year":"2020","unstructured":"Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463\u20139.","journal-title":"Nature"},{"issue":"12","key":"1222_CR41","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","volume":"8","author":"DE Leisman","year":"2020","unstructured":"Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233\u201344.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"1222_CR42","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/imt-2016-0020","volume":"8","author":"T Tanaka","year":"2016","unstructured":"Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959\u201370.","journal-title":"Immunotherapy"},{"issue":"6","key":"1222_CR43","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-2600(21)00139-9","volume":"9","author":"F Angriman","year":"2021","unstructured":"Angriman F, Ferreyro BL, Burry L, Fan E, Ferguson ND, Husain S, et al. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir Med. 2021;9(6):655\u201364.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"1222_CR44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41577-021-00553-8","volume":"21","author":"SA Jones","year":"2021","unstructured":"Jones SA, Hunter CA. Is IL-6 a key cytokine target for therapy in COVID-19? Nat Rev Immunol. 2021;21(6):337\u20139.","journal-title":"Nat Rev Immunol"},{"key":"1222_CR45","doi-asserted-by":"crossref","unstructured":"Group WHOREAfC-TW, Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326(6):499\u2013518.","DOI":"10.1001\/jama.2021.11330"},{"issue":"11","key":"1222_CR46","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41419-020-03151-z","volume":"11","author":"R Angioni","year":"2020","unstructured":"Angioni R, Sanchez-Rodriguez R, Munari F, Bertoldi N, Arcidiacono D, Cavinato S, et al. Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients. Cell Death Dis. 2020;11(11):957.","journal-title":"Cell Death Dis"},{"key":"1222_CR47","doi-asserted-by":"crossref","unstructured":"Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021;6(1).","DOI":"10.1172\/jci.insight.144455"},{"issue":"1","key":"1222_CR48","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","volume":"9","author":"H Han","year":"2020","unstructured":"Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123\u201330.","journal-title":"Emerg Microbes Infect"},{"key":"1222_CR49","first-page":"39","volume":"350","author":"EB Wilson","year":"2011","unstructured":"Wilson EB, Brooks DG. The role of IL-10 in regulating immunity to persistent viral infections. Curr Top Microbiol Immunol. 2011;350:39\u201365.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7","key":"1222_CR50","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1172\/JCI85996","volume":"126","author":"SA Younes","year":"2016","unstructured":"Younes SA, Freeman ML, Mudd JC, Shive CL, Reynaldi A, Panigrahi S, et al. IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. J Clin Invest. 2016;126(7):2745\u201356.","journal-title":"J Clin Invest"},{"issue":"3","key":"1222_CR51","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cyto.2012.05.020","volume":"59","author":"KC Verbist","year":"2012","unstructured":"Verbist KC, Klonowski KD. Functions of IL-15 in anti-viral immunity: multiplicity and variety. Cytokine. 2012;59(3):467\u201378.","journal-title":"Cytokine"},{"key":"1222_CR52","doi-asserted-by":"crossref","unstructured":"Cassatella MA, McDonald PP. Interleukin-15 and its impact on neutrophil function. Curr Opin Hematol. 2000;7(3):174\u20137.","DOI":"10.1097\/00062752-200005000-00008"},{"issue":"11","key":"1222_CR53","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm1492","volume":"12","author":"DG Brooks","year":"2006","unstructured":"Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006;12(11):1301\u20139.","journal-title":"Nat Med"},{"key":"1222_CR54","doi-asserted-by":"crossref","unstructured":"Chevrier S, Zurbuchen Y, Cervia C, Adamo S, Raeber ME, de Souza N, et al. A distinct innate immune signature marks progression from mild to severe COVID-19. Cell Rep Med. 2021;2(1):100166.","DOI":"10.1016\/j.xcrm.2020.100166"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01222-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-021-01222-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01222-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T20:08:42Z","timestamp":1726430922000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01222-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1222"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01222-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.18.21262258","asserted-by":"object"}]},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"15 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study included samples from patients enrolled in NCT04317040 at The Ohio State University Wexner Medical Center. Written or witnessed oral informed consent was obtained for each patient. This trial and protocol were approved by Western Institutional Review Board. The study was monitored continuously by a clinical monitor and a medical monitor from the contract research organization (CRO) who also generated safety reports submitted to an independent Data and Safety Monitoring Board (DSMB). Data quality control checks were performed and the medical monitor verified that the clinical trial was conducted, and data were generated in compliance with the protocol, International Conference on Harmonization Good Clinical Practice (ICH GCP), and all applicable regulatory requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}